GMED vs NVCR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

GMED

53.9
AI Score
VS
GMED Wins

NVCR

49.8
AI Score

Investment Advisor Scores

GMED

54score
Recommendation
HOLD

NVCR

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GMED NVCR Winner
Revenue 1.55B 357.64M GMED
Net Income 275.87M -86.80M GMED
Net Margin 17.8% -24.3% GMED
Operating Income 332.82M -77.98M GMED
ROE 5.8% -25.7% GMED
ROA 5.0% -10.9% GMED
Total Assets 5.49B 795.19M GMED
Cash 507.75M 93.70M GMED
Current Ratio 4.62 2.89 GMED
Free Cash Flow 339.32M -17.45M GMED

Relative Price Performance (Last 90 Days)

GMED 1M: -6.3% · 3M: -6.1% NVCR 1M: -16.2% · 3M: -13.7%

Current Technical Phase

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.6 · Price: $75.60

NVCR

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.5%), weak momentum, RSI 34

RSI (14): 34.3 · Price: $14.94

Fundamentals Snapshot

Metric GMED NVCR
Market Cap — —
Forward P/E 14.0 -18.3
Trailing P/E 19.2 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.2%
Gross Margin 0.7% 0.8%
Operating Margin 0.2% -0.1%
EPS 3.88 -1.30
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GMED is currently the stronger investment candidate, winning 10 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.